224 related articles for article (PubMed ID: 24789443)
1. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer.
Reeder-Hayes KE; Meyer AM; Dusetzina SB; Liu H; Wheeler SB
Breast Cancer Res Treat; 2014 Jun; 145(3):743-51. PubMed ID: 24789443
[TBL] [Abstract][Full Text] [Related]
2. Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer.
Felder TM; Do DP; Lu ZK; Lal LS; Heiney SP; Bennett CL
Breast Cancer Res Treat; 2016 May; 157(1):193-200. PubMed ID: 27120468
[TBL] [Abstract][Full Text] [Related]
3. Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer.
Reeder-Hayes K; Peacock Hinton S; Meng K; Carey LA; Dusetzina SB
J Clin Oncol; 2016 Jun; 34(17):2003-9. PubMed ID: 27069085
[TBL] [Abstract][Full Text] [Related]
4. A tracking and feedback registry to reduce racial disparities in breast cancer care.
Bickell NA; Shastri K; Fei K; Oluwole S; Godfrey H; Hiotis K; Srinivasan A; Guth AA
J Natl Cancer Inst; 2008 Dec; 100(23):1717-23. PubMed ID: 19033569
[TBL] [Abstract][Full Text] [Related]
5. Initiation of Adjuvant Endocrine Therapy in Black and White Women With Breast Cancer.
Sheppard VB; de Mendoza AH; He J; Jennings Y; Edmonds MC; Oppong BA; Tadesse MG
Clin Breast Cancer; 2018 Oct; 18(5):337-346.e1. PubMed ID: 29422259
[TBL] [Abstract][Full Text] [Related]
6. Adherence to Adjuvant Endocrine Therapy in Insured Black and White Breast Cancer Survivors: Exploring Adherence Measures in Patient Data.
Sheppard VB; He J; Sutton A; Cromwell L; Adunlin G; Salgado TM; Tolsma D; Trout M; Robinson BE; Edmonds MC; Bosworth HB; Tadesse MG
J Manag Care Spec Pharm; 2019 May; 25(5):578-586. PubMed ID: 31039059
[TBL] [Abstract][Full Text] [Related]
7. Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer.
Sail K; Franzini L; Lairson D; Du X
Ethn Health; 2012; 17(3):309-23. PubMed ID: 22066691
[TBL] [Abstract][Full Text] [Related]
8. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
[TBL] [Abstract][Full Text] [Related]
9. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
10. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
11. Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status.
Farias AJ; Du XL
Cancer Epidemiol Biomarkers Prev; 2017 Aug; 26(8):1266-1275. PubMed ID: 28515111
[No Abstract] [Full Text] [Related]
12. High Initiation of Adjuvant Hormonal Therapy Among Uninsured Stages I-III Breast Cancer Patients Treated in a Safety-Net Healthcare System.
Murphy CC; Tiro JA; Jean GW; Balasubramian BA; Alvarez CA
J Womens Health (Larchmt); 2017 Jun; 26(6):655-661. PubMed ID: 28296574
[TBL] [Abstract][Full Text] [Related]
13. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
Chen L; Li CI
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
[TBL] [Abstract][Full Text] [Related]
14. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
15. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Livaudais JC; Hershman DL; Habel L; Kushi L; Gomez SL; Li CI; Neugut AI; Fehrenbacher L; Thompson B; Coronado GD
Breast Cancer Res Treat; 2012 Jan; 131(2):607-17. PubMed ID: 21922245
[TBL] [Abstract][Full Text] [Related]
16. Patterns of care analysis among women with ductal carcinoma in situ in North Carolina.
Jackson LC; Camacho F; Levine EA; Anderson RT; Stewart JH
Am J Surg; 2008 Feb; 195(2):164-9. PubMed ID: 18096124
[TBL] [Abstract][Full Text] [Related]
17. Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.
Heiney SP; Truman S; Babatunde OA; Felder TM; Eberth JM; Crouch E; Wickersham KE; Adams SA
Am J Clin Oncol; 2020 Jul; 43(7):504-509. PubMed ID: 32251120
[TBL] [Abstract][Full Text] [Related]
18. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
[TBL] [Abstract][Full Text] [Related]
19. Factors That Contributed to Black-White Disparities in Survival Among Nonelderly Women With Breast Cancer Between 2004 and 2013.
Jemal A; Robbins AS; Lin CC; Flanders WD; DeSantis CE; Ward EM; Freedman RA
J Clin Oncol; 2018 Jan; 36(1):14-24. PubMed ID: 29035645
[TBL] [Abstract][Full Text] [Related]
20. Racial disparities in survival outcomes by breast tumor subtype among African American women in Memphis, Tennessee.
Vidal G; Bursac Z; Miranda-Carboni G; White-Means S; Starlard-Davenport A
Cancer Med; 2017 Jul; 6(7):1776-1786. PubMed ID: 28612435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
